文献速递白血病

青少年和年轻成人急性淋巴细胞白血病:按成人还是按儿童方案治疗?

Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?
PubMed 文献 · Blood · 2018-06-12

青少年和年轻成人(AYA)急性淋巴细胞白血病(ALL)是具有特定特征和需求的独特人群。15至20岁青少年使用完全儿童方案得到多项儿童与成人协作组比较研究的支持;在年轻成人中,越来越多的证据提示儿童启发或完全儿童方案也可能大幅改善结局,长期生存率接近70%,尽管造血干细胞移植指征在减少。近十年对ALL致癌景观随年龄分布的认识及微小残留病评估改善了风险分层,新靶点主要出现在异质性B-other组尤其费城样ALL亚组。儿童优异结果与AYA之间仍存的差距还涉及就医或入组试验延迟或困难、急性毒性增加及治疗依从性差等因素,应设计专门方案加以改善。

要点

  • 15至20岁青少年ALL使用完全儿童方案获多项儿童与成人协作组比较研究支持。
  • 年轻成人中儿童启发或完全儿童方案可能大幅改善结局,长期生存率接近70%。
  • 费城样ALL等B-other亚组需深入分子检测和靶向治疗特异性评估。

核心结论

  • AYA ALL是独特人群,15至20岁青少年使用完全儿童方案获多项比较研究支持,年轻成人中儿童启发或完全儿童方案可能大幅改善结局。

研究设计与样本

  • 本文为综述,汇总儿童与成人协作组比较研究及AYA ALL相关证据。

主要发现

  • 年轻成人采用儿童启发或完全儿童方案长期生存率接近70%,同时造血干细胞移植指征减少。
  • 近十年按年龄分布的ALL致癌景观知识和微小残留病评估改善了风险分层。
  • 新靶点主要出现在异质性B-other组,尤其费城样ALL亚组,需深入分子检测和靶向治疗特异性评估。
  • 儿童优异结果与AYA之间仍存的差距还涉及就医或入组试验延迟或困难、急性毒性增加及治疗依从性差。

关键数值与推荐

  • 15至20岁青少年使用完全儿童方案得到多项儿童与成人协作组比较研究支持。
  • 年轻成人中儿童启发或完全儿童方案可能使长期生存率接近70%。

临床怎么用

  • 应设计专门方案考虑就医或入组试验延迟或困难、急性毒性增加及治疗依从性差等因素,以改善AYA ALL患者生存和生活质量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) are recognized as a unique population with specific characteristics and needs. In adolescents age 15 to 20 years, the use of fully pediatric protocols is supported by many comparative studies of pediatric and adult cooperative groups. In young adults, growing evidence suggests that pediatric-inspired or even fully pediatric approaches may also dramatically improve outcomes, leading to long-term survival rates of almost 70%, despite diminishing indications of hematopoietic stem-cell transplantation. In the last decade, better knowledge of the ALL oncogenic landscape according to age distribution and minimal residual disease assessments has improved risk stratification. New targets have emerged, mostly in the heterogeneous B-other group, particularly in the Philadelphia-like ALL subgroup, which requires both in-depth molecular investigations and specific evaluations of targeted treatments. The remaining gap in the excellent results reported in children has many other contributing factors that should not be underestimated, including late or difficult access to care and/or trials, increased acute toxicities, and poor adherence to treatment. Specific programs should be designed to take into account those factors and finally ameliorate survival and quality of life for AYAs with ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Boissel N, Baruchel A. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? Blood. 2018. PMID: 29895662. doi:10.1182/blood-2018-02-778530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。